St.Shine Optical Co.,Ltd.

TPEX:1565 Stock Report

Market Cap: NT$11.6b

St.Shine OpticalLtd Valuation

Is 1565 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1565 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1565 (NT$229.5) is trading below our estimate of fair value (NT$482.95)

Significantly Below Fair Value: 1565 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1565?

Key metric: As 1565 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1565. This is calculated by dividing 1565's market cap by their current earnings.
What is 1565's PE Ratio?
PE Ratio18.4x
EarningsNT$627.96m
Market CapNT$11.57b

Price to Earnings Ratio vs Peers

How does 1565's PE Ratio compare to its peers?

The above table shows the PE ratio for 1565 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.8x
4107 Bioteque
17.8xn/aNT$8.9b
6782 Visco Vision
20.9x20.7%NT$12.9b
4129 United Orthopedic
20.9xn/aNT$9.4b
4126 Pacific Hospital Supply
15.7x5.6%NT$6.5b
1565 St.Shine OpticalLtd
18.4x18.4%NT$11.6b

Price-To-Earnings vs Peers: 1565 is good value based on its Price-To-Earnings Ratio (18.4x) compared to the peer average (18.8x).

Price to Earnings Ratio vs Industry

How does 1565's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
1565 18.4xIndustry Avg. 19.6xNo. of Companies10PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1565 is good value based on its Price-To-Earnings Ratio (18.4x) compared to the TW Medical Equipment industry average (19.6x).

Price to Earnings Ratio vs Fair Ratio

What is 1565's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1565 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.4x
Fair PE Ratio16.6x

Price-To-Earnings vs Fair Ratio: 1565 is expensive based on its Price-To-Earnings Ratio (18.4x) compared to the estimated Fair Price-To-Earnings Ratio (16.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1565 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNT$229.50
NT$261.00
+13.7%
8.4%NT$290.00NT$237.00n/a3
Nov ’25NT$213.50
NT$223.33
+4.6%
9.0%NT$238.00NT$195.00n/a3
Oct ’25NT$210.50
NT$199.50
-5.2%
2.3%NT$204.00NT$195.00n/a2
Jul ’25NT$187.50
NT$182.50
-2.7%
6.8%NT$195.00NT$170.00n/a2
Jun ’25NT$183.00
NT$195.00
+6.6%
2.1%NT$200.00NT$190.00n/a3
May ’25NT$187.50
NT$197.00
+5.1%
2.5%NT$203.00NT$190.00n/a4
Apr ’25NT$191.50
NT$197.00
+2.9%
2.5%NT$203.00NT$190.00n/a4
Mar ’25NT$202.50
NT$197.00
-2.7%
2.5%NT$203.00NT$190.00n/a4
Feb ’25NT$190.00
NT$197.00
+3.7%
2.5%NT$203.00NT$190.00n/a4
Jan ’25NT$190.00
NT$197.00
+3.7%
2.5%NT$203.00NT$190.00n/a4
Dec ’24NT$191.00
NT$197.00
+3.1%
2.5%NT$203.00NT$190.00n/a4
Nov ’24NT$182.00
NT$212.50
+16.8%
7.8%NT$230.00NT$190.00NT$213.504
Oct ’24NT$192.50
NT$224.25
+16.5%
9.7%NT$250.00NT$190.00NT$210.504
Sep ’24NT$196.00
NT$224.40
+14.5%
8.6%NT$250.00NT$190.00NT$177.505
Aug ’24NT$217.00
NT$234.40
+8.0%
5.8%NT$250.00NT$215.00NT$178.505
Jul ’24NT$231.50
NT$254.33
+9.9%
14.5%NT$330.00NT$215.00NT$187.506
Jun ’24NT$243.50
NT$254.33
+4.4%
14.5%NT$330.00NT$215.00NT$183.006
May ’24NT$249.00
NT$260.17
+4.5%
13.3%NT$330.00NT$215.00NT$187.506
Apr ’24NT$259.00
NT$257.50
-0.6%
13.7%NT$330.00NT$215.00NT$191.506
Mar ’24NT$258.00
NT$252.43
-2.2%
17.5%NT$330.00NT$192.00NT$202.507
Feb ’24NT$259.50
NT$248.86
-4.1%
18.2%NT$330.00NT$192.00NT$190.007
Jan ’24NT$246.50
NT$253.14
+2.7%
17.1%NT$330.00NT$192.00NT$190.007
Dec ’23NT$250.00
NT$253.14
+1.3%
17.1%NT$330.00NT$192.00NT$191.007
Nov ’23NT$212.00
NT$266.71
+25.8%
15.7%NT$330.00NT$192.00NT$182.007

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.3b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$215.50

7D

1.9%

1Y

-27.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

7D

0.4%

1Y

2.6%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$29.95

7D

-3.1%

1Y

-19.1%